Stoke Therapeutics, Inc. SEC filings STOK

Stoke Therapeutics, Inc. has 632 filings in SEC EDGAR's recent list, going back to Nov 24, 2014. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.

Stoke Therapeutics, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 22, 2026 —
DEF 14A Proxy statement Apr 22, 2026 Jun 3, 2026
DEFA14A Additional proxy material Apr 22, 2025 —
DEF 14A Proxy statement Apr 22, 2025 Jun 3, 2025
DEFA14A Additional proxy material Apr 23, 2024 —
DEF 14A Proxy statement Apr 23, 2024 Jun 5, 2024
DEF 14A Proxy statement Sep 28, 2023 Oct 24, 2023
PRE 14A Preliminary proxy statement Sep 18, 2023 Sep 15, 2023
DEFA14A Additional proxy material May 24, 2023 —
DEFA14A Additional proxy material Apr 27, 2023 —
DEF 14A Proxy statement Apr 27, 2023 Jun 13, 2023
PRE 14A Preliminary proxy statement Apr 17, 2023 Jun 13, 2023
DEFA14A Additional proxy material Apr 26, 2022 —
DEF 14A Proxy statement Apr 26, 2022 Jun 7, 2022
DEFA14A Additional proxy material Apr 26, 2021 —
DEF 14A Proxy statement Apr 26, 2021 Jun 8, 2021
DEFA14A Additional proxy material Apr 21, 2020 —
DEF 14A Proxy statement Apr 21, 2020 Jun 3, 2020

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
STOK (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Bedford, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1623526
Former names
ASOthera Pharmaceuticals, Inc. (until Nov 24, 2014)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.